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Case Report
Neurological improvement of perineural and
leptomeningeal spread of squamous cell
carcinoma treated with intrathecal
chemotherapy and systemic EGFR inhibition
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Turpin2,3 & Santosh Kesari*,1
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Centre, 1081 BT Amsterdam, The Netherlands
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at Providence Saint John’s Health Center, Santa Monica, CA 90404, USA
3Department of Neurosciences, Moores Cancer Center, University of California San Diego, La Jolla, CA 92093, USA
* Author for correspondence: Tel.: +1 310 829 8265; kesaris@jwci.org
Squamous cell carcinoma (SCC) is a common cancer of the skin. Risk factors include fair skin, excessive
sun and ultraviolet light exposure, and history of xeroderma pigmentosa. Perineural invasion (PNI), an
uncommon manifestation of SCC, involves microscopic tumor cells invading various layers of the nerve
sheath. It is associated with a poorer prognosis. Standard treatment for PNI includes radiation therapy.
Here, we describe a case an older gentleman with a history of SCC with PNI successfully treated with
erlotinib and intrathecal chemotherapy.
First draft submitted: 16 March 2017; Accepted for publication: 4 May 2017; Published online: 6 October
2017
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Practice points
 Perineural invasion (PNI), an uncommon manifestation of squamous cell carcinoma (SCC), is associated with a
poor prognosis.
 Findings of cranial neuropathy in clinical examination of patients with SCC may suggest PNI.
 MRI PNI findings may include enlargement or abnormal enhancement of the nerve.
 It is important to be observant of perineural spread for SCC and always consider the possibility of leptomeningeal
metastasis.
 Adjuvant radiation therapy is considered one of the limited treatment options for SCC with PNI, particularly in
patients where surgery is not a viable option.
 Intrathecal chemotherapy has become the mainstay of treatment in leptomeningeal metastasis.
 High expression of EGFR in cutaneous SCC makes EGFR inhibitors a rational choice in patients with advanced
disease.
Cutaneous squamous cell carcinoma (SCC), the second most common skin cancer worldwide, has a substantial
risk of metastasis in contrast to basal cell carcinoma, the most prevalent form that carries less risk of metastases [1].
Perineural invasion (PNI) is a rare pathologic feature associated with SCCs with a reported incidence ranging from
3 to 6% [2,3]. This under-recognized route of metastasis can account for distant tumor spread well beyond local
invasion, especially leptomeningeal metastasis (LM). Although the pathogenesis remains incompletely understood,
PNI seems to play a role in many different malignancies such as pancreas, colon, rectum, prostate and head and
neck cancers [4].
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Case presentation
A 68-year old Caucasian male with history of SCC in the left temple was seen in our clinic for evaluation of facial
numbness. He has a history of hyperlipidemia, hypertension and a triple vessel coronary artery bypass graft for
coronary artery disease. 2 years prior, he had left temple SCC treated with Mohs micrographic surgery with negative
margins. He presents now with numbness on the left side of his face that includes the upper lip. The symptom was
initially attributed to scar tissue. Shortly after, he developed a nodule in the left buccal area. A biopsy of the nodule
revealed SCC that was immediately treated with local radiotherapy. 1 year later, another nodule appeared in the
left temple area for which he completed another course of radiotherapy.
A few months after radiotherapy, he started to experience horizontal diplopia and an eye exam showed medial
deviation of his left eye. A neurological exam revealed trigeminal nerve paresthesia of the left face and paresis of
the left abducens and facial nerve. He was prescribed dexamethasone 4 mg oral daily. MRI of his face and brain
showed extensive perineural spread along the ophthalmic (V1), maxillary (V2) and mandibular (V3) branches of the
left trigeminal nerve proximal to the left cavernous sinus, Meckel’s cave and cisternal segment. There was evidence
of denervation atrophy of the left muscles of mastication. The cancer spread around the left facial nerve and mild
asymmetric, abnormal enhancement of the dura along the left middle cranial fossa (Figure 1A & B). Spinal MRI
showed nonspecific 5-mm nodular thickening and enhancement within the left posterolateral thecal sac, which was
highly suspicious of leptomeningeal neoplastic disease (Figure 1C). The lumbar puncture showed no malignant
or atypical cells, but revealed elevated white blood cells of 48 (normal: 0–10 mm3) and elevated total protein at
80 mg/dl (normal: 15–45 mg/dl).
The combination of the results from his spinal MRI and his cerebrospinal fluid (CSF) sample increased the clinical
suspicion of LM. The decision was made to immediately start aggressive treatment with intrathecal chemotherapy
consisting of cytarabine liposome injection (Depocyt R©) 50 mg and methotrexate (MTX) 12 mg every 2 weeks.
In addition, radiotherapy to the left cavernous sinus and adjacent areas of involvement was delivered with 54
Gray in 30 fractions. Treatment with cetuximab (Erbitux R©), an EGFR inhibitor, was initiated after radiation at
a loading dose of 400 mg/m2, followed by a weekly standard dose of 250 mg/m2. CSF sample taken before
administration of his second dose of intrathecal chemotherapy showed large atypical cells. The patient tolerated the
first three sessions with minimal side effects. Shortly after the fourth treatment, the patient experienced an episode
of chemical meningitis after suffering from dehydration, a known side effect of the intrathecal chemotherapy
agents. This event, and two subsequent cytologies that were negative for malignant cells, prompted a reduction
of intrathecal chemotherapy treatments to once every month. A follow-up MRI of face and brain 3 months later
showed overall mixed response. The previously described enhancement along the left medial middle cranial fossa
and the trigeminal nerve decreased, however, new soft tissue enhancement was seen at the left lateral aspect of the
maxilla, inferior alveolar nerve and external auditory canal. Due to the ambivalence of the MRI images, the patient
was sent for a fluorine-18-fluorodeoxyglucose positron emission tomography scan of his head and body. This
showed mild fluorine-18-fluorodeoxyglucose activity consistent with MRI findings, possibly reflecting treatment
effect. The rest of the body showed no abnormal foci of uptake. Clinically, his neurological symptoms remained
stable with notable improvement in his left facial movement. Treatment-related toxicities included minimal rash
on his face and chest consistent with an anti-EGFR effect from the cetuximab.
There were two palpable small nodules in the subcutaneous tissue at the inferior aspect of the left lower eyelid
that appeared to be increasing in size. The lesions were removed and cetuximab was discontinued. Pathology results
revealed SCC with extensive PNI. The patient was switched to a daily regimen of erlotinib (Tarceva R©) 150 mg. Aside
from a mild rash and diarrhea, he experienced no side effects. Restaging MRI scans showed a stable intracranial
disease with a decrease in the previously described enhancement along the left medial aspect of middle cranial
fossa (Figure 2). There were no new cutaneous malignant lesions noted during physical examination. Neurological
exam showed resolution of his left abducens nerve palsy and diplopia. He showed evidence of radiographic and
neurological clinical stability for more than a year after the initial diagnosis. However, he developed multiple medical
complications and prolonged hospitalizations and erlotinib was held. He never recovered from his medical illnesses
and eventually developed neurological progression confirmed on imaging of the brain and spine (Figure 3) and
died of acute cardiorespiratory cause. An autopsy showed evidence of continued SCC in nerves and leptomeninges.
Discussion
PNI from SCC has been recognized as an important negative prognostic factor in overall survival [5]. Cutaneous
SCCs have been sporadically described to cause neurological symptoms due to PNI. The majority of these patients
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Figure 1. T1 MRI of the brain and spinal cord postgadolinium. (A & B) Abnormal signal intensity in the cavernous sinus. (C) Abnormal
signal intensity noted throughout spinal cord, especially in lumbosacral region.
present with cranial neuropathy, with possible extension to the skull base. The local control rate at this time remains
at 25% [6]. LM in cutaneous SCCs with evidence of CSF involvement is extremely rare and has only been described
in five cases [7–10]. At this stage of the disease, treatment remains palliative and stabilizing or diminishing neurological
deficits. LM occurs when retrograde dissemination of malignant cells along the nerve cause tumor invasion of the
meninges and CSF. This can be viewed as the most devastating consequence of PNI. Due to the blood–brain
barrier (BBB), the cancer cells that reach the CSF will encounter relative protection from the host’s defensive
immune system. As a result, they can freely migrate throughout the CNS and reattach by directly traversing the
pial membrane into the spinal cord or nerves [11]. The prognosis is poor for patients diagnosed with LM and the
median survival time of treated patients is only 4–6 months [12]. Due to the limited BBB penetration of systemic
chemotherapeutic agents, intrathecal chemotherapy has become the mainstay of treatment in LM. Studies show
that both liposomal cytarabine and MTX have individually treated LM effectively [13]. A general high expression of
EGFR in cutaneous SCC makes EGFR inhibitors a rational choice in patients with advanced disease. Erlotinib has
been approved for the treatment of non-small-cell lung cancer and pancreatic cancer [14]. Experience in aggressive
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Figure 2. T1 MRI of the brain postgadolinium. (A & B) Decreased signal intensity in the cavernous sinus after erlotinib treatment.
Figure 3. T1 MRI of the brain postgadolinium. (A) Abnormal
signal intensity surrounding right lateral ventricle. (B) Increased
signal intensity diffusely noted throughout posterior aspect of
spinal cord.
cutaneous SCC is limited but promising. Complete and partial responses were seen in patients who failed all other
therapies in several case reports [15,16]. A literature review identified five cases of leptomeningeal dissemination of
a primary cutaneous SCC with evidence of CSF involvement [7–10]. These cases have been summarized in Table 1.
Due to the limited number of patients, no standard treatment exists. In most cases, treatment only consisted of
radiotherapy [7–9], while one patient received concomitant intravenous MTX [7]. To the best of our knowledge, this
is the first case description of a cutaneous SCC with LM spread successfully treated with intrathecal chemotherapy.
These patients unfortunately have a poor prognosis. No patient survived beyond 6 months after diagnosing LM;
however, our patient survived well over 12 months after his diagnosis. This excellent response might be partly
attributable to the early diagnosis of LM. Contrary to other patients [13–16], our patient had not shown any clinical
signs of widespread LM when diagnosis occurred. It is important to be observant of perineural spread for SCC and
always consider the possibility of LM. This report shows that intrathecal chemotherapy with Depocyt (cytarabine
liposome injection) and MTX, and systemic EGFR inhibitors could result in neurologic disease control in LM
from SCC.
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Table 1. Case reports of cutaneous squamous cell carcinomas with leptomeningeal metastasis.
Study (year) Age Presenting
symptom
CSF evidence of
LM
Imaging
evidence of LM
Radiation after
LM
Chemotherapy
after LM
Survival after
LM
Ref.
Begemann et al.
(2003)
72 Weakness hips Malignant cells MRI: nodular
enhancement
thoracic cord
Spinal lesions
(3575 cGy in
13 Fr)
Three courses IV
MTX
(3500 mg/m2)
every other
week
6 months [7]
59 Confusion SCC cells MRI: LM
enhancement
craniocervical
junction
Local Rx (dose
not specified)
– 3 months
Zhu et al. (2004) 70 Lower extremity
paresis
Malignant cells MRI: enhancing
cauda equina
and nerve roots
Cranial base
(3700 cGy) and
lumbosacral
spine (3650 cGy)
– Not mentioned
(hospice
discharge after
1 month)
[8]
Sullivan and
Smee (2006)
51 Leg paresis,
paresthesia and
pain
High total
protein: 1.55 g/l
(0.15–0.45 g/l),
no malignant
cells
MRI: multiple
enhancing
nodules cervical
and lumbar
spine
Whole spine Rx
(35 Gy in 15 Fr)
– 4 months [9]
Skripuletz et al.
(2010)
68 Mental changes,
headaches and
unstable gait
Malignant cells CT: multiple
intracranial
lesions with
enhancing LM
region
– – 2 weeks [10]
CSF: Cerebrospinal fluid; CT: Computed tomography; IT: Intrathecal; IV: Intravenous; LM: Leptomeningeal metastasis; MTX: Methotrexate; Rx: Radiation; SCC: Squamous cell carcinoma.
Conclusion & future perspective
Although perineural spread is common in the setting of SCC, there exists a rare possibility of LM. In patients
where surgery is not an option, radiotherapy is the widely accepted treatment. While prognosis for patients with
LM remains poor, early recognition of LM may improve outcomes. Currently, radiotherapy and IT chemotherapy
are used as standard treatments for PNI. Despite these treatments, prognosis remains poor. EGFR inhibitors, such
as erlotinib, are being considered as alternative options for PNI. As mentioned above, our patient’s symptoms and
neurological function improved after receiving erlotinib. More studies need to be completed to verify erlotinib’s
effects in the treatment of PNI in patients with SCC.
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